Immunocore announces the dosing of the first patient for chronic Hepatitis B with the ImmTAV® bispecific molecule
Immunocore Holdings Plc today announces the dosing of the first patient in the first-in-human clinical trial of IMC- 109V to treat patients with chronic hepatitis B (HBV) infection. Wholly owned IMC-I ...